
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is a buy with a PT of $19 due to their strong financials and potential growth opportunities. Their cash and equivalents at the end of 4Q25 were $265M, and they have a positive outlook for their lead products, Ibsrela and Xphozah, as well as a potential expansion of Ibsrela's label to include chronic idiopathic constipation. The recent Phase 3 trial for Ibsrela in CIC anticipates enrollment completion by YE26, and a potential sNDA filing in 2H27. Overall, Ardelyx is well positioned to capture a significant portion of the market in both the IBS-C and CKD-related hyperphosphatemia spaces, and the potential expansion into CIC provides additional upside to their already strong financials and growth prospects.
Bears say
Ardelyx is expected to face increased operating expenses in FY26 as it invests in its SG&A infrastructure and advances its drug Tenapanor, branded as IBSRELA, in a Phase 3 study for Chronic Idiopathic Constipation (CIC). While the company expects strong revenue growth for both IBSRELA and XPHOZAH, these revenue targets may be challenging to achieve given the limited market potential and competition in the targeted segments. Additionally, the success of the CIC indication and differentiation of IBSRELA will be crucial to driving long-term growth and maintaining investor confidence.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares